Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CERO

CERo Therapeutics 5/15/2025 Earnings Report

CERo Therapeutics logo
$0.01 0.00 (-0.84%)
As of 10:10 AM Eastern
ProfileEarnings HistoryForecast

CERo Therapeutics EPS Results

Actual EPS
-$31.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CERo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CERo Therapeutics Announcement Details

Quarter
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CERo Therapeutics' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

CERo Therapeutics Earnings Headlines

CERo Therapeutics Holdings Secures New Consolidated Financing Facility
August 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cero-therapeutics-holdings-secures-new-consolidated-financing-facility?utm_source=marketbeat.com&utm_medium=referral
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of ...
August 31, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/srx-global-acquires-senior-secured-debt-in-cero-therapeutics-holdings-inc-an-innovative-cellular-immunotherapy-company-with-cancer-fighting-molecule-for-the-treatment-of-hematologic-cancers-1036507198
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
September 25 at 1:00 AM  |  Chaikin Analytics (Ad)
CERo Therapeutics Expands Convertible Debt Financing Arrangement
July 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cero-therapeutics-expands-convertible-debt-financing-arrangement?utm_source=marketbeat.com&utm_medium=referral
Nasdaq, Inc.: Delisting of Securities from The Nasdaq Stock Market
July 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68999143-nasdaq-inc-delisting-of-securities-from-the-nasdaq-stock-market-399.htm
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
June 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/cero/option-chain
See More CERo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email.

About CERo Therapeutics

CERo Therapeutics (NASDAQ:CERO) is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancer. The company’s technology is designed to expand the capabilities of conventional T cells by combining targeted tumor-cell recognition and killing with phagocytic activity, potentially enabling immune cells to engulf and eliminate malignant cells.

CERo’s lead product candidate is CER-1236, an engineered T-cell therapy directed at CD123, a cell-surface protein expressed on several hematologic malignancies, including acute myeloid leukemia. The company has been advancing CER-1236 toward clinical development and is evaluating its potential in patients with relapsed or refractory blood cancers. Its broader research programs are focused on applying the company’s engineered-cell platform to additional oncology targets.

The company was established to develop next-generation cellular immunotherapies and became publicly traded through a business combination with Phoenix Biotech Acquisition Corp. in 2024. CERo Therapeutics is focused primarily on research, development and clinical testing rather than commercial product sales, and its therapies are not yet broadly available.

View CERo Therapeutics Profile
Earnings Tools